Glenn A. Smith

Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily

D. Hoelscher, Y. Lou, G. Yuen, 2004, Antimicrobial Agents and Chemotherapy.

Interlaboratory Measurement Differences in Intracellular Carbovir Triphosphate Concentrations in HIV‐Infected Patients: Sources of Variability in Processing, Shipping, and Quantitation

R. Haubrich, D. Richman, Sonia Jain, 2010, Journal of clinical pharmacology.

An Automated Method for the Determination of Montelukast in Human Plasma Using Dual-Column HPLC Analysis and Peak Height Summation of the Parent Compound and Its Photodegradation Product

Glenn A Smith, Cynthia M. Rawls, R. Kunka, 2004, Pharmaceutical Research.

Toxicity and toxicokinetics of metformin in rats.

J. Polli, J. Nold, Glenn A Smith, 2010, Toxicology and applied pharmacology.

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5

P. Watkins, E. Schuetz, P. Stewart, 2005, Clinical pharmacology and therapeutics.

Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design

J. Polli, D. Nunez, M. Bush, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.